These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 29057203)

  • 21. Single-agent immunosuppression after liver transplantation: what is possible?
    Raimondo ML; Burroughs AK
    Drugs; 2002; 62(11):1587-97. PubMed ID: 12109922
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Steroid or calcineurin inhibitor-sparing immunosuppressive protocols.
    Grinyó JM; Cruzado JM
    Contrib Nephrol; 2005; 146():30-42. PubMed ID: 15567918
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Review of immunosuppressive usage in pancreas transplantation.
    Stratta RJ
    Clin Transplant; 1999 Feb; 13(1 Pt 1):1-12. PubMed ID: 10081628
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mesenchymal Stromal Cells for Transplant Tolerance.
    Podestà MA; Remuzzi G; Casiraghi F
    Front Immunol; 2019; 10():1287. PubMed ID: 31231393
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New frontiers in immunosuppression.
    Benvenuto LJ; Anderson MR; Arcasoy SM
    J Thorac Dis; 2018 May; 10(5):3141-3155. PubMed ID: 29997983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nanoparticle-Based Modulation and Monitoring of Antigen-Presenting Cells in Organ Transplantation.
    Ochando J; Braza MS
    Front Immunol; 2017; 8():1888. PubMed ID: 29312352
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Kidney transplantation under a tolerogenic regimen of recipient pretreatment and low-dose postoperative immunosuppression with subsequent weaning.
    Shapiro R; Jordan ML; Basu A; Scantlebury V; Potdar S; Tan HP; Gray EA; Randhawa PS; Murase N; Zeevi A; Demetris AJ; Woodward J; Marcos A; Fung JJ; Starzl TE
    Ann Surg; 2003 Oct; 238(4):520-5; discussion 525-7. PubMed ID: 14530723
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identifying risk profiles in liver transplant candidates and implications for induction immunosuppression.
    Cillo U; Bechstein WO; Berlakovich G; Dutkowski P; Lehner F; Nadalin S; Saliba F; Schlitt HJ; Pratschke J
    Transplant Rev (Orlando); 2018 Jul; 32(3):142-150. PubMed ID: 29709248
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of hyperglycaemia after pancreas transplantation: are new immunosuppressants the answer?
    Egidi FM
    Drugs; 2005; 65(2):153-66. PubMed ID: 15631539
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tolerance induction by removal of alloreactive T cells: in-vivo and pruning strategies.
    Watson D; Hu M; Zhang GY; Wang YM; Alexander SI
    Curr Opin Organ Transplant; 2009 Aug; 14(4):357-63. PubMed ID: 19610169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunosuppression: today, tomorrow, and withdrawal.
    Hirose R; Vincenti F
    Semin Liver Dis; 2006 Aug; 26(3):201-10. PubMed ID: 16850369
    [TBL] [Abstract][Full Text] [Related]  

  • 32. From immunosuppression to tolerance.
    Adams DH; Sanchez-Fueyo A; Samuel D
    J Hepatol; 2015 Apr; 62(1 Suppl):S170-85. PubMed ID: 25920086
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New perspectives of immunosuppression.
    Halleck F; Friedersdorff F; Fuller TF; Matz M; Huber L; Dürr M; Schütz M; Budde K
    Transplant Proc; 2013 Apr; 45(3):1224-31. PubMed ID: 23622665
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regulatory T cells: first steps of clinical application in solid organ transplantation.
    van der Net JB; Bushell A; Wood KJ; Harden PN
    Transpl Int; 2016 Jan; 29(1):3-11. PubMed ID: 25981203
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunologic tolerance for immune system-mediated diseases.
    Hackett CJ; Dickler HB
    J Allergy Clin Immunol; 1999 Mar; 103(3 Pt 1):362-70. PubMed ID: 10069866
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunosuppression in pediatric solid organ transplantation.
    Agarwal A; Pescovitz MD
    Semin Pediatr Surg; 2006 Aug; 15(3):142-52. PubMed ID: 16818135
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pro and anti-neoplastic effects of immunosuppressive drug in renal transplantation].
    Infante B; Stallone G; Schena A; Maiorano A; Gesualdo L; Schena FP; Grandaliano G
    G Ital Nefrol; 2006; 23(4):389-95. PubMed ID: 17063439
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nanomedicine for immunosuppressive therapy: achievements in pre-clinical and clinical research.
    Al-Lawati H; Aliabadi HM; Makhmalzadeh BS; Lavasanifar A
    Expert Opin Drug Deliv; 2018 Apr; 15(4):397-418. PubMed ID: 29261332
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunosuppressive therapy after kidney transplantation: current and new strategies.
    Metalidis C; Kuypers D
    Minerva Urol Nefrol; 2011 Mar; 63(1):1-19. PubMed ID: 21336242
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current status of liver transplantation in children.
    McDiarmid SV
    Pediatr Clin North Am; 2003 Dec; 50(6):1335-74. PubMed ID: 14710783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.